SEBI Reg. Investment Advisor

Download App

MoneyWorks4Me

Suven Life Sciences trades in fine fettle on the bourses

13 Nov 2017 Evaluate

Suven Life Sciences is currently trading at Rs. 202.75, up by 4.70 points or 2.37 % from its previous closing of Rs. 198.05 on the BSE.

The scrip opened at Rs. 201.60 and has touched a high and low of Rs. 203.75 and Rs. 199.00 respectively. So far 32477 shares were traded on the counter.

The BSE group 'B' stock of face value Rs. 1 has touched a 52 week high of Rs. 230.00 on 17-Oct-2017 and a 52 week low of Rs. 155.00 on 11-Aug-2017.

Last one week high and low of the scrip stood at Rs. 216.20 and Rs. 196.25 respectively. The current market cap of the company is Rs. 2543.74 crore.

The promoters holding in the company stood at 60.00%, while institutions and non-institutions held 7.92% and 32.08% respectively.

Suven Life Sciences is participating and presenting positive Pre-clinical and Phase-1 clinical data of several advanced molecules from their portfolio of new chemical entities (NCEs) and the status of Phase 2 clinical trial of their lead compound SUVN-502 at Neuroscience 2017, organized by Society for Neuroscience being held at Washington DC, USA during 13-15 November 2017. These data presentations highlight Suven’s continued commitment to explore new treatment options addressing unmet medical need through novel mechanisms and targets.

Suven Life Science is a biopharmaceutical company focused on discovering, developing and commercializing novel pharmaceutical products, which are first in class or best in class CNS therapies using GPCR targets.

 

Suven Life Sciences Share Price

195.90 -0.10 (-0.05%)
17-Apr-2026 16:59 View Price Chart
Peers
Company Name CMP
Sun Pharma Inds. 1675.20
Dr. Reddys Lab 1235.40
Cipla 1238.30
Zydus Lifesciences 942.55
Lupin 2324.25
View more..

About MoneyWorks4Me

MoneyWorks4Me is a SEBI-registered Investment Adviser (IA) dedicated to helping investors build long-term wealth through transparent, research-driven, conflict-free guidance. Founded in 2008, we started our journey as a Research Analyst (RA), providing deep fundamental analysis, intrinsic value insights, and long-term investing frameworks for Indian equities. In 2017, we transitioned to a full-fledged SEBI-registered Investment Adviser, strengthening our commitment to acting as a fiduciary—always putting the investor’s interest first.

Our Vision

To become India’s most trusted, research-powered fiduciary advisory platform—where every investor, regardless of experience, can make calm, confident, and well-reasoned investment decisions.

What Makes MoneyWorks4Me Different

Our Approach: Ensuring compounding work its magic on client portfolio.

MoneyWorks4Me ensures this through:

×